It’s the just known nucleoside analog in clinical development for the treating RSV currently. ALS-8176 demonstrates powerful anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step of progress in the development of more effective treatments for this serious and often existence threatening disease. The randomized, double-blind, placebo-controlled, Phase 1 research of orally administered ALS-8176 will assess safety, tolerability, and pharmacokinetics of one ascending doses and multiple ascending dosages in healthy volunteers.African Mango sure includes a shot!

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity funding of $1 million with a single institutional investor, 88 Seaside, L.P.32 per share. Separately, Adeona announced the completion of 75 percent enrollment in Part 2 of Adeona’s 60 patient clinical study of oral Zinthionein ZC for Alzheimer’s disease and slight cognitive impairment entitled, A Potential, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer’s Disease . The CopperProof-2 study represents the 1st controlled clinical research of oral zinc therapy for Alzheimer’s disease and mild cognitive impairment.